Innate and adaptive immunity plays a critical role in the defence of the lung and other mucosal surfaces exposed to micro-organisms. Anti-microbial peptides and proteins, cytokines and chemokines are important immune weapons as they build up the protective front for the respiratory tract. The notion that susceptibility to infectious diseases may be inherited is widely accepted and, as it is the failure to activate adaptive immunity that may allow infection to become established and progress toward invasion and dissemination, the recognition of specific gene defects affecting the ability of the immune system to overcome invading pathogens may shed light upon those mechanisms of immune regulation that are playing the most critical roles. The aim of the present review is to discuss some of the advances in infection immunogenetics that may lead to identify new strategies in the development of new anti-infectious and anti-inflammatory drugs.

Keywords:
Pneumonia, Natural and acquired immunity, Animal models, Gene polymorphisms
1.
Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 2005;340:207–214.
2.
Benacerraf B, McDevitt HO: Histocompatibility-linked immune response genes. Science 1972;175:273–279.
3.
Teran-Escandon D, Teran-Ortiz L, Camarena-Olvera A, Gonzalez-Avila G, Vaca-Marin MA, Granados J, Selman M: Human leukocyte antigen-associated susceptibility to pulmonary tuberculosis: molecular analysis of class II alleles by DNA amplification and oligonucleotide hybridization in Mexican patients. Chest 1999;115:428–433.
4.
Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, Balakrishnan K, Pitchappan RM: Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 1999;79:309–317.
5.
Amirzargar AA, Yalda A, Hajabolbaghi M, Khosravi F, Jabbari H, Rezaei N, Niknam MH, Ansari B, Moradi B, Nikbin B: The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004;8:1017–1021.
6.
Naik E, LeBlanc S, Tang J, Jacobson LP, Kaslow RA: The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-1-seropositive whites. J Acquir Immune Defic Syndr 2003;33:140–145.
7.
Lin M, Kuang Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, Chen PJ, Su YW, Lim KH, Tsai ZU, Lin ZY, Lin RS, Huang CH: Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003;4:9.
8.
Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782–787.
9.
Gordon S: Pattern recognition receptors: doubling up for the innate immune response. Cell 2002;111:927–930.
10.
Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immunol 2000;68:6398–6401.
11.
Moore CE, Segal S, Berendt AR, Hill AV, Day NP: Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 2004;1:1194–1197.
12.
Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187–191.
13.
Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SFJ: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. Infect Dis 2002;186:1522–1525.
14.
Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028–1032.
15.
Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A: Toll-like receptor 4 polymorphisms are associated with resistance to legionnaires’ disease. Proc Natl Acad Sci USA 2005;102:2487–2489.
16.
Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A, Ozinsky A, Smith KD, Aderem A: A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires’ disease. J Exp Med 2003;198:1563–1572.
17.
Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, Rothe G, Schmitz G: Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29:557–561.
18.
Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Rothe G, Schmitz G: The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000;1:405–407.
19.
Gibot S, Cariuo A, Drouet L, Rossignol M, Ripoll L: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002;30:969–973.
20.
Roy S, Knox K, Segal S,Griffiths D, Moore CE, Welsh KL, Smarason A, Day NP, McPheat WL, Crook DW, Hill AV: MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002;359:1569–1573.
21.
Garred P, Strom JJ, Quist L, Taaning E, Madsen HO: Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003;188:1394–1403.
22.
Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710–720.
23.
Kohashi O, Ono T, Ohki K, Soejima T, Moriya T, Umeda A, Meno Y, Amako K, Funakosi S, Masuda M, et al: Bactericidal activities of rat defensins and synthetic rabbit defensins on staphylococci, Klebsiella pneumoniae (Chedid, 277, and 8N3), Pseudomonas aeruginosa (mucoid and nonmucoid strains), Salmonella typhimurium (Ra, Rc, Rd, and Re of LPS mutants) and Escherichia coli. Microbiol Immunol 1992;36:369–380.
24.
Cole AM, Waring AJ: The role of defensins in lung biology and therapy. Am J Respir Med 2002;1:249–259.
25.
Bals R, Hiemstra PS: Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004;23:327–333.
26.
Sahl HG, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A: Mammalian defensins: structures and mechanism of antibiotic activity. J Leukoc Biol 2005;77:466–475.
27.
Ihi T, Nakazato M, Mukae H, Matsukura S: Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis 1997;25:1134–1140.
28.
Ashitani J, Mukae H, Nakazato M, Taniguchi H, Ogawa K, Kohno S, Matsukura S: Elevated pleural fluid levels of defensins in patients with empyema. Chest 1998;113:788–794.
29.
Ashitani J, Mukae H, Arimura Y, Sano A, Tokojima M, Nakazato M: High concentrations of alpha-defensins in plasma and bronco-alveolar lavage fluid of patients with acute respiratory distress syndrome. Life Sci 2004;75:1123–1134.
30.
van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS: Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol 1999;104:1131–1138.
31.
Sakamoto N, Mukae H, Fujii T, Ishii H, Yoshioka T, Sugiyama K, Mizuta Y, Kadota J, Nakazato M, Kohno S: Differential effects of alpha- and beta-defensin on cytokine production by cultured human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:L508–L513.
32.
van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS: Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000;278:L51–L58.
33.
Aarbiou J, Verhoosel RM, Van Wetering S, De Boer WI, Van Krieken JH, Litvinov SV, Rabe KF, Hiemstra PS: Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Respir Cell Mol Biol 2004;30:193–201.
34.
Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, Ganz T, Randell SH, Modlin RL: Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol 2003;171:6820–6826.
35.
Radhakrishnan Y, Hamil KG, Yenugu S, Young SL, French FS, Hall SH: Identification, characterization, and evolution of a primate beta-defensin gene cluster. Genes Immun 2005;6:203–210.
36.
Dork T, Stuhrmann M: Polymorphisms of the human beta-defensin-1 gene. Mol Cell Probes 1998;12:171–173.
37.
Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S: A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-infection in Italian children. AIDS 2004;18:1598–1600.
38.
Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA: Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high throughput SNP assays and association with Candida carriage in type-1 diabetics and nondiabetics controls.J Clin Microbiol 2003;41:90–96.
39.
Sharma S, Verma I, Khuller GK: Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001;45:639–640.
40.
Giles FJ, Rodriguez R, Weisford D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaisse EJ, Bolwell BJ, Chao NJ, Shea TC, Brunvand MM, Vaughan W, Petersen F, Schubert M, Lazarus HM, Maziarz RT, Silverman M, Beveridge RA, Redman R, Pulliam JG, Devitt-Risse P, Fuchs HJ, Hurd DD: A phase III, randomised, double-bind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004;28:559–565.
41.
Yoshida K, Matsumoto T, Tateda K, Uchida K, Tsujimoto S, Iwakurai Y, Yamaguchi K: Protection against pulmonary infection with Klebsiella pneumoniae in mice by interferon-gamma through activation of phagocytic cells and stimulation of production of other cytokines. J Med Microbiol 2001;50:959–964.
42.
Moore TA, Perry ML, Getsoian AG, Newstead MW, Standiford TJ: Divergent role of gamma interferon in a murine model of pulmonary versus systemic Klebsiella pneumoniae. Infect Immun 2002;70:6310–6318.
43.
Shinozawa Y, Matsumoto T, Uchida K, Tsujimoto S, Iwakura Y, Yamaguchi K: Role of interferon-gamma in inflammatory responses in murine pulmonary infection with Legionella pneumophila. J Med Microbiol 2002;51:225–230.
44.
Deng JC, Tateda K, Zeng X, Standiford TJ: Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun 2001;69:6382–6390.
45.
Bot A, Bot S, Bona CA: Protective role of gamma interferon during recall response to influenza virus. J Virol 1998;72:6637–6645.
46.
Deng JC, Zeng X, Newstead M, Moore TA, Tsai WC, Thannickal VJ, Standiford TJ: STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella pneumoniae. J Immunol 2004;173:4075–4083.
47.
Bot A, Holz A, Christen U, Wolfe T, Temann A, Flavell R, von Herrath M: Local IL-4 expression in the lung reduces pulmonary influenza-virus specific secondary cytotoxic responses. Virology 2000;269:66–77.
48.
Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK: Interleukin-17 and lung host defence against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001;25:335–340.
49.
Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK: Requirement of interleukin 17 receptor signalling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defence. J Exp Med 2001;194:519–527.
50.
Lauw FN, Branger J, Florquin S, Speelman P, van Deventer SJ, Akira S, van der Poll T: IL-18 improves the early antimicrobial host defence to pneumococcal pneumonia. J Immunol 2002;168:372–378.
51.
Liu B, Mori I, Hossain MJ, Dong L, Takeda K, Kinura Y: Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 2004;85:423–428.
52.
Schultz MJ, Knapp S, Florquin S, Pater J, Takeda K, Akira S, van der Poll T: Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun 2003;71:1630–1634.
53.
Graham MB, Braciale VL, Braciale TJ: Influenza virus-specific CD4+ Th 2 lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994;180:1273–1282.
54.
Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC: Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683–691.
55.
Jones HP, Tabor L, Sun X, Woolard MD, Simecka JW: Depletion of CD8+ T cells exacerbates CD4+ Th cell-associated inflammatory lesions during murine mycoplasma respiratory disease. J Immunol 2002;168:3493–3501.
56.
Magee DM, Williams DM, Smith JG, Bleicker CA, Grubbs BG, Schachter J, Rank RG: Role of CD8 T cells in primary Chlamydia infection. Infect Immun 1995;63:516–521.
57.
Steele C, Zheng M, Young E, Marrero L, Shellito JE, Kolls JK: Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells. Infect Immun 2002;70:5208–5215.
58.
Moore TA, Moore BB, Newstead MW, Standiford TJ: Gamma-delta T cells are critical for survival and early proinflammatory cytokine gene expression during murine Klebsiella pneumoniae infection. J Immunol 2000;165:2643–2650.
59.
Fang XM, Schroder S, Hoeft A, Stuber F: Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330–1334.
60.
Ma P, Chen D, Pan J, Du B: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002;30:1046–1050.
61.
Beutler B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 1989;7:625–635.
62.
Dotti C, D’Apice MR, Rogliani P, Novelli G, Saltini C, Amicosante M: Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:29–34.
63.
Waterer GW, Quasney MW, Cantor RM, Wunderink RG: Septic shock and respiratory failure community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001;163:1599–1604.
64.
Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, Van Aken H, Assmann G, Berendes E: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002;30:32–37.
65.
Schaaf BM,Boemke F, Esnaashar H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K: Pneumococcal septic shock is associated with the interleukin-10 –1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003;168:476–480.
66.
Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, O’Neill SJ: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58:154–156.
67.
Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003;124:1103–1115.
68.
Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912–918.
69.
Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997;112:164–172.
70.
Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumour necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697–1702.
71.
Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733–742.
72.
Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836–1843.
73.
McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1–5.
74.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM: KyberSept Trial Study Group.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869–1878.
75.
Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH: Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1–126.
76.
Bavington C, Page C: Stopping bacterial adhesion: a novel approach to treating infections. Respiration 2005;72:335–344.
77.
Cazzola M, Matera MG, Pezzato G: Inflammation – a new therapeutic target in pneumonia. Respiration 2005;72:117–126.
78.
Cazzola M, Saltini C: Novel approaches to the treatment of bacterial lower respiratory tract infections: introduction. Respiration 2005;72:7–8.
79.
Blasi F, Tarsia P, Aliberti S: Strategic targets of essential host-pathogen interactions. Respiration 2005;72:9–25.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.